Oncolytics Biotech Inc. (ONCY): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONCY Stock Price Chart Interactive Chart >
ONCY Price/Volume Stats
| Current price | $1.78 | 52-week high | $2.28 |
| Prev. close | $1.83 | 52-week low | $0.80 |
| Day low | $1.77 | Volume | 87,561 |
| Day high | $1.83 | Avg. volume | 190,800 |
| 50-day MA | $1.71 | Dividend yield | N/A |
| 200-day MA | $1.35 | Market Cap | 109.16M |
Oncolytics Biotech Inc. (ONCY) Company Bio
Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.
Latest ONCY News From Around the Web
Below are the latest news stories about ONCOLYTICS BIOTECH INC that investors may wish to consider to help them evaluate ONCY as an investment opportunity.
The Oncolytics Biotech Inc. (ONCY) had a good session last reading, didn’t it?As of Friday, Oncolytics Biotech Inc.’s (NASDAQ:ONCY) stock closed at $1.63, up from $1.62 the previous day. While Oncolytics Biotech Inc. has overperformed by 0.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ONCY rose by 17.27%, with highs and lows ranging from $2.28 to $0.80, […] |
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year. |
Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer SymposiumOncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González C |
What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track TagOncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication. |
ONCY Price Returns
| 1-mo | 9.20% |
| 3-mo | 36.92% |
| 6-mo | 42.63% |
| 1-year | -6.32% |
| 3-year | -32.06% |
| 5-year | -67.76% |
| YTD | 9.20% |
| 2022 | 17.27% |
| 2021 | -41.60% |
| 2020 | -50.00% |
| 2019 | 162.98% |
| 2018 | -66.46% |
Loading social stream, please wait...